艾滋病合并巨细胞病毒视网膜炎患者抗逆转录病毒治疗时机的多中心前瞻性随机对照试验研究方案
本研究为在中国17家医院开展的前瞻性随机对照试验,计划纳入300例艾滋病合并巨细胞病毒视网膜炎患者,按1:1随机分为早期启动抗逆转录病毒治疗组(抗巨细胞病毒治疗后2周内)和延迟启动组(抗巨细胞病毒治疗2周后),随访48周,主要结局为视力丧失发生率。
要点
- 拟纳入300例艾滋病合并巨细胞病毒视网膜炎患者,随机分为早期与延迟启动抗逆转录病毒治疗组。
- 主要结局为48周随访期内视力丧失(视力差于20/40或20/200)的发生率。
- 次要结局包括HIV病毒学抑制、CD4+ T细胞计数、死亡率、视网膜炎进展等。
核心结论
- 研究旨在探讨艾滋病合并巨细胞病毒视网膜炎患者启动抗逆转录病毒治疗的最佳时机,以期提供可靠的临床证据。
研究设计与样本
- 前瞻性随机对照试验,在中国大陆17家医院开展。
- 计划纳入300例巨细胞病毒视网膜炎患者,按1:1随机分为早期启动组(抗巨细胞病毒治疗后2周内启动抗逆转录病毒治疗)和延迟启动组(抗巨细胞病毒治疗2周后启动)。
- 所有参与者接受抗巨细胞病毒治疗启动后48周随访。
关键数值与推荐
- 主要结局为48周随访期内两组视力丧失(视力差于20/40或20/200)的发生率。
- 次要结局包括HIV病毒学抑制和血清CD4+ T细胞计数变化、死亡率、视网膜炎进展(CMV病灶外周边缘移动≥½视盘直径或出现新CMV病灶)、视网膜脱离、免疫恢复性葡萄膜炎及其他机会性感染和不良事件的发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytomegalovirus retinitis (CMVR) is an important opportunistic infection (OI) occurring mainly in patients with acquired immunodeficiency syndrome (AIDS) and has the potential to cause severe visual impairment and blindness among AIDS patients. Subsequent to the adoption and implementation of widespread antiretroviral therapy (ART), the prognosis of AIDS-associated CMVR has been substantially improved. Nevertheless, the equivocal clinical evidence as regards the optimal timing for ART initiation in patients with an established CMVR diagnosis is required. We therefore designed the present study in order to investigate the optimal timing for ART initiation in AIDS/CMVR patients. METHODS: This will be a prospective, randomized controlled trial to be performed at 17 hospitals in mainland China. A total of 300 participants with CMVR will be randomly assigned to an early ART initiation group (ART initiation within 2 weeks after anti-CMV therapy), or a deferred ART initiation group (initiation of ART more than 2 weeks after anti-CMV therapy) at a 1:1 ratio. All participants will receive 48 weeks of follow-up after anti-CMV therapy initiation. Our primary outcome will be the incidence of visual loss (to a visual acuity worse than 20/40 or 20/200) in the two groups during the 48-week follow-up period. Secondary outcomes will include changes in HIV virological suppression and serum CD4+ T-cell counts, the incidence of mortality, retinitis progression (movement of the peripheral border of a CMV lesion ≥ ½ disc diameter, or occurrence of a new CMV lesion), retinal detachment, immune recovery uveitis (IRU), and other OIs and adverse events between the two study groups during the 48 weeks of follow-up. DISCUSSION: The study aims to investigate the optimal timing for ART initiation in AIDS/CMVR patients. We hope to be able to extract robust clinical evidence for use in optimal AIDS/CMVR management should our trial be successful. TRIAL REGISTRATION: This research was registered as one of the twelve clinical trials under the name of a general project "A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections", ChiCTR1900021195. Registered on 1 February 2019, http://www.chictr.org.cn/showproj.aspx?proj=35362 .
引用
- He XQ, Huang YQ, Zeng YM, et al. Timing of antiretroviral therapy for HIV-infected patients with cytomegalovirus retinitis: study protocol of a multi-center prospective randomized controlled trial. Trials. 2021. PMID: 33736696. doi:10.1186/s13063-021-05159-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。